BioInvent is focused on developing novel immuno-modulatory antibodies for cancer therapy. BioInvent’s innovative antibodies may significantly improve the efficacy of currently available immuno-modulatory checkpoint inhibitor therapies and/or activate anti-cancer immunity in currently non-responding patients and cancer types.
- FcγRllB >
- BI-1206 in non-Hodgkins lymphoma and chronic lymphocytic leukemia >
- BI-1206 in combination with pembrolizumab in solid tumors >
- BT-001 - Partnership with Transgene – developing next generation oncolytic viruses expressing an anti-CTLA-4 antibody to treat solid tumors >
- BI-1808 (anti-TNFR2) in solid tumors and CTCL >
- Preclinical pipeline >